Keywords: Eisai, Fycompa, Epilepsy, Novartis, Lucentis, Diabetic macular edema, NHS Scotland

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

Article | 11 December 2012

Print This

Japanese drug major Eisai’s (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now approved for use in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in